FDA Grants Priority Review To GlaxoSmithKline’s Tykerb

Nov. 16 (Bloomberg) -- GlaxoSmithKline Plc said the U.S. Food and Drug Administration gave fast-track status to its application for the experimental drug Tykerb for breast cancer, the most common cancer among women.

>>> Discuss This Story